Primary High-Risk Human Papillomavirus Testing for Cervical Cancer Screening in the United States: Is It Time?

Flanagan, Melina

doi:10.5858/arpa.2018-0001-ra

Cited by 28 publications

(19 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…High‐income countries such as the United States and Canada employ primary HPV testing (test with higher sensitivity) followed by cytology (test with higher specificity) for cervical cancer screening . The USFDA approved HPV testing instead of the Pap test for cervical cancer screening in April 2014 . The 2015 Interim guidelines have recommended Roche cobas HPV test for primary cervical cancer screening of women over 25 years without concurrent Pap smear testing .…”

Section: Introductionmentioning

confidence: 99%

Diagnostic accuracy of self‐collected vaginal samples for HPV DNA detection in women from South India

Kuriakose

Sabeena

Ravishankar

et al. 2020

Intl J Gynecology & Obste

View full text Add to dashboard Cite

Objectives: To assess the efficacy of self-collected vaginal samples compared with physician-collected cervical samples for the detection of HPVDNA. Methods: A hospital-based cross-sectional study was carried out among patients with newly diagnosed cervical cancer attending . Consenting patients collected their vaginal samples, followed by cervical sample collection by the clinician. The paired samples were transported at 4-8 °C to the laboratory. Amplification of LCR/E6/E7 regions of the HPV genome was done by polymerase chain reaction (PCR). The agreement level between paired samples was assessed by the Kappa index.Results: Among the 114 cervical cancer patients enrolled in the present cross-sectional study, the prevalence of HPV DNA was 78.1% (95% confidence interval [CI] 69.2%-85%) in cervical samples and 77.2% in vaginal samples (95% CI 68.7%-83.9%). The overall agreement between the two sampling methods was 93.9% and the kappa value was 0.82 (P<0.001). The sensitivity of HPV detection using vaginal samples was 98.9% (95% CI 93.9%-99.8%) and the specificity was 100% (95% CI 86.7%-100%) with cervical sampling as the gold standard. By Kappa index, an almost perfect agreement for HPV DNA detection between self-collected and physician-collected samples was observed. Conclusion:Self-collection of vaginal samples ensures equity of cervical cancer screening in low-income countries such as India. K E Y W O R D S

show abstract

Section: Introductionmentioning

confidence: 99%

Diagnostic accuracy of self‐collected vaginal samples for HPV DNA detection in women from South India

Kuriakose

Sabeena

Ravishankar

et al. 2020

Intl J Gynecology & Obste

View full text Add to dashboard Cite

show abstract

“…Cervical cancer ranks as the second [28] most common gynecological cancer type and poses a great threat to women's health. In most cases, patients have already progressed into an advanced stage when they are diagnosed.…”

Section: Discussionmentioning

confidence: 99%

The New Biomarker for Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (CESC) Based on Public Database Mining

Ding

Xiong

Fan

et al. 2020

BioMed Research International

View full text Add to dashboard Cite

To reconstruct the ceRNA biological network of cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC) and to select an appropriate mRNA as a biomarker that could be used for CESC early diagnosis and prognosis evaluation. We downloaded CESC data from the TCGA public database, and statistical analysis was conducted with the R software to find out differential expressed genes encoding for lncRNAs, miRNAs, and mRNAs. The differentially expressed mRNAs (DEmRNAs) screened in the ceRNA network were analyzed for survival to find the mRNAs with significantly linked to the survival prognosis. These mRNAs were searched in the Pathological Atlas to identify the final appropriate mRNAs. Differential expression analysis revealed 773 lncRNAs, 94 miRNAs, and 2466 mRNAs. Survival analysis of DEmRNAs in the ceRNA network indicated that ADGRF4, ANXA8L1, HCAR3, IRF6, and PDE2A (P<0.05) were negatively correlated with survival time. Verification of these six DEmRNAs in the Pathology Atlas indicated that PDE2A was a possible biomarker for CESC patients. PDE2A might be a biomarker for early diagnosis and prognosis evaluation of CESC patients, but due to the lack of available data, further studies may be needed for confirmation.

show abstract

“…Cervical cancer is one of the most common malignancies in the female reproductive system. 1 However, the initial stages of cervical cancer are usually asymptomatic. 2 Thus, a certain number of specific and sensitive non-invasive biomarkers are urgently needed to predict the prognosis of cervical cancer.…”

Section: Introductionmentioning

confidence: 99%

<p>Long Non-Coding RNA HULC Promotes Cervical Cancer Cell Proliferation, Migration and Invasion via miR-218/TPD52 Axis</p>

Lu¹,

Wan²,

Tao³

et al. 2020

OTT

View full text Add to dashboard Cite

Objective: Long non-coding RNAs (lncRNAs) have been identified as important players in tumorigenesis. LncRNA highly upregulated in liver cancer (HULC) has been identified as a key regulator in the progression of various cancers. However, the functional role and the mechanisms of HULC in regulating cervical cancer cell behavior remain unclear. Methods: HULC expression, miR-218 expression and TPD52 mRNA level in cervical cancer cells were examined by qRT-PCR. Cell proliferation was evaluated by MTT assay. Cell migration and invasion were examined by Transwell assay. TPD52 protein level was measured by Western blot. Dual-luciferase reporter assay was measured to verify the combination of HULC and miR-218 as well as miR-218 and TPD52. Results: HULC expression was upregulated in cervical cancer cell lines, and HULC promoted cervical cancer cell proliferation, migration and invasion. Mechanistically, HULC acted as a sponge of miR-218 to elevate expression of TPD52, a target of miR-218, and thereby promoted cervical cancer cell proliferation, migration, and invasion. Conclusion: HULC promotes cervical cancer cell proliferation, migration and invasion via miR-218/TPD52 axis.

show abstract

Primary High-Risk Human Papillomavirus Testing for Cervical Cancer Screening in the United States: Is It Time?

Cited by 28 publications

References 31 publications

Diagnostic accuracy of self‐collected vaginal samples for HPV DNA detection in women from South India

Diagnostic accuracy of self‐collected vaginal samples for HPV DNA detection in women from South India

The New Biomarker for Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (CESC) Based on Public Database Mining

<p>Long Non-Coding RNA HULC Promotes Cervical Cancer Cell Proliferation, Migration and Invasion via miR-218/TPD52 Axis</p>

Contact Info

Product

Resources

About